title: Treatment of malignant gastric outlet obstruction with endoscopically placed self-expandable metal stents.
abstract: Malignant gastroduodenal obstruction can occur in up to 20% of patients with primary pancreatic, gastric or duodenal carcinomas. Presenting symptoms include nausea, vomiting, abdominal distention, pain and decreased oral intake which can lead to dehydration, malnutrition, and poor quality of life. Endoscopic stent placement has become the primary therapeutic modality because it is safe, minimally invasive, and a cost-effective option for palliation. Stents can be successfully deployed in the majority of patients. Stent placement appears to lead to a shorter time to symptomatic improvement, shorter time to resumption of an oral diet, and shorter hospital stays as compared with surgical options. Recurrence of the obstructive symptoms resulting from stent occlusion, due to tumor ingrowth or overgrowth, can be successfully treated with repeat endoscopic stent placement in the majority of the cases. Both endoscopic stenting and surgical bypass are considered palliative treatments and, to date, no improvement in survival with either modality has been demonstrated. A tailored therapeutic approach, taking into consideration patient preferences and involving a multidisciplinary team including the therapeutic endoscopist, surgeon, medical oncologist, radiation therapist, and interventional radiologist, should be considered in all cases.
authors.affiliation: Department of Gastroenterology, Hepatology and Nutrition, University of Florida, Gainesville, FL 32610, United States.
authors.forename: Jill K J
authors.initials: JK
authors.lastname: Gaidos
authors.forename: Peter V
authors.initials: PV
authors.lastname: Draganov
mesh_terms: D016099:Endoscopy, Gastrointestinal / Q000009:adverse effects; D017219:Gastric Outlet Obstruction / Q000209:etiology / Q000601:surgery*; D005770:Gastrointestinal Neoplasms / Q000150:complications; D006801:Humans; D010166:Palliative Care / Q000379:methods*; D015607:Stents / Q000009:adverse effects; D016896:Treatment Outcome